The EGFR Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the EGFR gene in the A-549 human lung adenocarcinoma epithelial cell line. This product provides a heterogeneous pool of cells that have undergone gene editing, enabling functional studies of EGFR loss in a non-small cell lung cancer (NSCLC) context without the need for clonal isolation.
A-549 cells are epithelial in origin and display typical characteristics of lung adenocarcinoma, including expression of oncogenic markers. They are extensively used as a model system for studying the molecular mechanisms of NSCLC and for preclinical drug evaluation. These cells endogenously express wild-type EGFR and are sensitive to EGFR-targeted therapies, making them an ideal host for assessing the impact of EGFR loss on tumorigenic properties.
EGFR is a receptor tyrosine kinase that, upon ligand binding by EGF, TGF-alpha, or amphiregulin, dimerizes and autophosphorylates, recruiting adaptor proteins GRB2, SOS, and SHC. This triggers activation of the RAS-RAF-MEK-ERK cascade and the PI3K-AKT-mTOR axis, with PTEN providing negative regulation. The ERK and AKT pathways modulate transcription factors to control expression of downstream targets including MYC, CCND1, and BCL2, promoting cell cycle progression and survival. Additionally, EGFR signaling can engage the JAK/STAT pathway, further influencing cell fate. Knockout of EGFR therefore eliminates these proliferative and survival signals.
In the A-549 NSCLC model, EGFR knockout results in loss of ligand-induced signaling, as evidenced by decreased phosphorylation of ERK and AKT. This model is critical for studying EGFR-dependent tumor growth, exploring resistance mechanisms to EGFR tyrosine kinase inhibitors such as erlotinib and gefitinib, and identifying alternative signaling networks that compensate for EGFR loss. The polyclonal population more accurately mimics the genetic diversity found in tumors, providing a robust system for investigating heterogeneous drug responses.
Key applications include immunoblotting for EGFR and its downstream effectors (phospho-ERK, phospho-AKT), quantitative RT-PCR to confirm mRNA silencing, functional assays measuring cell proliferation, migration, and invasion, and high-throughput drug sensitivity screens. Researchers can also employ these cells to discover synthetic lethal partners or to evaluate off-target CRISPR effects. For detailed protocols and support, please contact Ascent Research.
